Study of LY5625573 in Healthy People and Those with Inflammation
Treatments studied
This study tests a new medicine called LY5625573 in healthy volunteers and people with mild inflammation (measured by a blood test called C-reactive protein). It helps researchers understand how the medicine works in the body and if it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 21 and 65 years old (if you are in Singapore, this must be at the time you sign up).
- You must be generally healthy, with normal blood test results and no significant medical conditions.
- You must meet weight requirements: for most parts, your body mass index (BMI) should be between 18.5 and 32. For a special group with inflammation, BMI can be up to 40.
- You must have good kidney function, measured by a blood test (eGFR). The exact level depends on which part of the study you join.
- You must not have a history of active or latent tuberculosis, serious infections, or certain other infections like herpes zoster.
- You must not have any heart rhythm problems or other significant abnormalities on an electrocardiogram (ECG).
- You must not have had serious allergic reactions to any medication, especially to medicines related to LY5625573 (VTX3232).
- You must not have had recent suicidal thoughts or depression symptoms that are considered severe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called LY5625575 in healthy people and in people with inflammation (measured by a blood test called C-reactive protein). The goal is to see if the drug is safe and how the body processes it.
This is a Phase 1 study testing a new medicine called LY4178256. It will check how the drug is processed by the body and its safety in healthy volunteers. The results help doctors understand how to dose the drug in future studies.
This study tests a new medicine called LY4226695 in healthy people to see how safe it is and how the body handles it. It is an early-stage trial, and participating may help develop a new treatment option.
This trial tests a new medicine called LY4088044 in healthy people to see how it affects the body. It helps doctors learn about the drug's safety before testing it in patients with a disease.
This is an early-stage study testing a new experimental medicine called LY4302814 in healthy volunteers to see if it is safe and how the body processes it. By enrolling healthy people first, researchers can understand the drug's basic safety profile before testing it in patients with medical conditions.
This trial tests a new medicine, currently known by the code LY4355756, in healthy people to check its safety and how the body handles it. Your participation could help show if this medicine is safe enough to move into larger testing.
Hear when a new C-Reactive Protein trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.